Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Apellis Pharmaceuticals Inc (APLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 18.00 (-2.86%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 18.00 (-2.86%)
Apellis Pharmaceuticals Reports First Quarter 2019 Business Update and Financial Results

Resumed Dosing in Phase 3 Geographic Atrophy Program

APLS : 18.00 (-2.86%)
Consolidated Research: 2019 Summary Expectations for Wyndham Hotels & Resorts, Apellis Pharmaceuticals, Transcat, Emerald Expositions Events, Capitala Finance, and Seres Therapeutics -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Wyndham Hotels & Resorts Inc. (NYSE:WH),...

WH : 55.39 (-0.91%)
MCRB : 4.13 (-4.18%)
TRNS : 24.30 (-0.21%)
CPTA : 8.97 (+0.56%)
APLS : 18.00 (-2.86%)
EEX : 12.69 (-0.78%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 18.00 (-2.86%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 18.00 (-2.86%)
Florida Poly Unveils Plans for State-of-the-Art Research Building

Florida Polytechnic University announced plans to build another iconic building on its campus that will serve as a research hub for the Central Florida region, becoming a magnet for high-tech development...

APLS : 18.00 (-2.86%)
U.S. Army Awards ARA Contract for Its Cutting-Edge Augmented Reality Software

The U.S. Army awarded Applied Research Associates, Inc. (ARA) a sole-source contract in January to integrate its patent-protected state-of-the-art Augmented Reality software (ARC4: Augmented Reality, Command,...

APLS : 18.00 (-2.86%)
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 18.00 (-2.86%)
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 18.00 (-2.86%)
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 18.00 (-2.86%)
Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy

No inflammation observed in ten patients dosed in Phase 1b trial with new intravitreal APL-2 drug product from modified manufacturing process

APLS : 18.00 (-2.86%)
Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals(R) for APL-2 in Hematologic Indications

Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement

APLS : 18.00 (-2.86%)
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

Phase 3 Geographic Atrophy Program Expected to Restart By or In Q2 2019

APLS : 18.00 (-2.86%)
Apellis Pharmaceuticals' APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria

New designation now includes all PNH patients

APLS : 18.00 (-2.86%)
Apellis' APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia

Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system,...

APLS : 18.00 (-2.86%)
Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe

CRESTWOOD, Ky., WALTHAM, Mass. and ZUG, Switzerland, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development...

APLS : 18.00 (-2.86%)
Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher

Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

APLS : 18.00 (-2.86%)
ACOR : 11.02 (-4.42%)

Van Meerten Stock Picks

Aaon - Pick of the Day
My Stock Pick of the Day is the HVAC company AAON (AAON).
AAON -0.40
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar